Emine Olcay Yasa

Emine Olcay Yasa

Auto-generated profile, based on publicly available information

Emine Olcay Yasa

İstanbul Medeniyet Üniversitesi

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Jornal de Pediatria
Verified
Journal Article
Open access
Ener Cagri DinleyiciEner Cagri Dinleyici
Ener Cagri Dinleyici
NDNazan Dalgic
Nazan Dalgic
SGSirin Guven
Sirin Guven
OMOzge Metin
Ozge Metin
OYOlcay Yasa
Olcay Yasa
YVYvan Vandenplas
Yvan Vandenplas
Two randomized controlled clinical trials have shown that Lactobacillus (L) reuteri DSM 17938 reduces the duration of diarrhea in children hospitalized due to acute infectious diarrhea. This was the first trial evaluating the efficacy of L. reuteri DSM 17938 in outpatient children with acute infectious diarrhea. This was a multicenter, randomized, single-blinded, case control clinical trial in children with acute watery diarrhea. A total of 64 children who presented at outpatient clinics were enrolled. The probiotic group received 1×10(8)CFU L. reuteri DSM 17938 for five days in addition to oral rehydration solution (ORS) and the second group was treated with ORS only. The primary endpoint was the duration of diarrhea (in hours). The secondary endpoint was the number of children with diarrhea at each day of the five days of intervention. Adverse events were also recorded. The mean duration of diarrhea was significantly reduced in the L. reuteri group compared to the control group (approximately 15h, 60.4±24.5h [95% CI: 51.0-69.7h] vs. 74.3±15.3h [95% CI: 68.7-79.9h], p<0.05). The percentage of children with diarrhea was lower in the L. reuteri group (13/29; 44.8%) after 48h than the control group (27/31; 87%; RR: 0.51; 95% CI: 0.34-0.79, p<0.01). From the 72nd hour of intervention onwards, there was no difference between the two groups in the percentage of children with diarrhea. No adverse effects related to L. reuteri were noted. L. reuteri DSM 17938 is effective, safe, and well-tolerated in outpatient children with acute infectious diarrhea.

12 June 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
Ener Cagri DinleyiciEner Cagri Dinleyici
Ener Cagri Dinleyici
DMDaniel Martínez-Martínez
Daniel Martínez-Martínez
AKAtes Kara
Ates Kara
AKAdem Karbuz
Adem Karbuz
NDNazan Dalgic
Nazan Dalgic
Andrés MoyaAndrés Moya
Andrés Moya
Gut microbiota is closely related to acute infectious diarrhea, one of the leading causes of mortality and morbidity in children worldwide. Understanding the dynamics of the recovery from this disease is of clinical interest. This work aims to correlate the dynamics of gut microbiota with the evolution of children who were suffering from acute infectious diarrhea caused by a rotavirus, and their recovery after the administration of a probiotic, Saccharomyces boulardii CNCM I-745. The experiment involved 10 children with acute infectious diarrhea caused by a rotavirus, and six healthy children, all aged between 3 and 4 years. The children who suffered the rotavirus infection received S. boulardii CNCM I-745 twice daily for the first 5 days of the experiment. Fecal samples were collected from each participant at 0, 3, 5, 10, and 30 days after probiotic administration. Microbial composition was characterized by 16S rRNA gene sequencing. Alpha and beta diversity were calculated, along with dynamical analysis based on Taylor's law to assess the temporal stability of the microbiota. All children infected with the rotavirus stopped having diarrhea at day 3 after the intervention. We observed low alpha diversities in the first 5 days (p-value < 0.05, Wilcoxon test), larger at 10 and 30 days after probiotic treatment. Canonical correspondence analysis (CCA) showed differences in the gut microbiota of healthy children and of those who suffered from acute diarrhea in the first days (p-value < 0.05, ADONIS test), but not in the last days of the experiment. Temporal variability was larger in children infected with the rotavirus than in healthy ones. In particular, Gammaproteobacteria class was found to be abundant in children with acute diarrhea. We identified the microbiota transition from a diseased state to a healthy one with time, whose characterization may lead to relevant clinical data. This work highlights the importance of using time series for the study of dysbiosis related to diarrhea.

1 August 2015 in Beneficial Microbes
Verified
Journal Article
Closed access
Ener Cagri DinleyiciEner Cagri Dinleyici
Ener Cagri Dinleyici
AKA. Kara
A. Kara
NDN. Dalgic
N. Dalgic
ZKZ. Kurugol
Z. Kurugol
Vefik ARICAVefik ARICA
Vefik ARICA
YVY. Vandenplas
Y. Vandenplas
Evidence from the literature has shown thatSaccharomyces boulardiiprovides a clinically significant benefit in the treatment of acute infectious diarrhoea in children. In this multicentre, randomised, prospective, controlled, single blind clinical trial performed in children with acute watery diarrhoea, we aimed to evaluate the impact ofS. boulardiiCNCM I-745 in hospitalised children, in children requiring emergency care unit (ECU) stay and in outpatient settings. The primary endpoint was the duration of diarrhoea (in hours). Secondary outcome measures were duration of hospitalisation and diarrhoea at the 3rdday of intervention. In the whole study group (363 children), the duration of diarrhoea was approximately 24 h shorter in theS. boulardiigroup (75.4±33.1 vs 99.8±32.5 h,P<0.001). The effect ofS. boulardii(diarrhoea-free children) was observed starting at 48 h. After 72 h, only 27.3% of the children receiving probiotic still had watery diarrhoea, in contrast to 48.5% in the control group (P<0.001). The duration of diarrhoea was significantly reduced in the probiotic group in hospital, ECU and outpatient settings (P<0.001,P<0.01 andP<0.001, respectively). The percentage of diarrhoea-free children was significantly larger after 48 and 72 h in all settings. The mean length of hospital stay was shorter with more than 36 h difference in theS. boulardiigroup (4.60±1.72 vs 6.12±1.71 days,P<0.001). The mean length of ECU stay was shorter with more than 19 h difference in the probiotic group (1.20±0.4 vs 2.0±0.3 days,P<0.001). No adverse effects related to the probiotic were noted. Because treatment can shorten the duration of diarrhoea and reduce the length of ECU and hospital stay, there is likely a social and economic benefit ofS. boulardiiCNCM I-745 in adjunction to oral rehydration solution in acute infectious gastroenteritis in children.

16 December 2011 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
Ener Cagri DinleyiciEner Cagri Dinleyici
Ener Cagri Dinleyici
VGVARICOMP Study Group
VARICOMP Study Group
ZKZafer Kurugol
Zafer Kurugol
OTOzden Turel
Ozden Turel
NHNevin Hatipoglu
Nevin Hatipoglu
SASaadet Akarsu
Saadet Akarsu
Varicella can cause complications that are potentially serious and require hospitalization. Our current understanding of the causes and incidence of varicella-related hospitalization in Turkey is limited and sufficiently accurate epidemiological and economical information is lacking. The aim of this study was to estimate the annual incidence of varicella-related hospitalizations, describe the complications, and estimate the annual mortality and cost of varicella in children. VARICOMP is a multi-center study that was performed to provide epidemiological and economic data on hospitalization for varicella in children between 0 and 15 years of age from October 2008 to September 2010 in Turkey. According to medical records from 27 health care centers in 14 cities (representing 49.3% of the childhood population in Turkey), 824 children (73% previously healthy) were hospitalized for varicella over the 2-year period. Most cases occurred in the spring and early summer months. Most cases were in children under 5 years of age, and 29.5% were in children under 1 year of age. The estimated incidence of varicella-related hospitalization was 5.29–6.89 per 100,000 in all children between 0–15 years of age in Turkey, 21.7 to 28 per 100,000 children under 1 year of age, 9.8–13.8 per 100,000 children under 5 years of age, 3.96–6.52 per 100,000 children between 5 and 10 years of age and 0.42 to 0.71 per 100,000 children between 10 and 15 years of age. Among the 824 children, 212 (25.7%) were hospitalized because of primary varicella infection. The most common complications in children were secondary bacterial infection (23%), neurological (19.1%), and respiratory (17.5%) complications. Secondary bacterial infections (p < 0.001) and neurological complications (p < 0.001) were significantly more common in previously healthy children, whereas hematological complications (p < 0.001) were more commonly observed in children with underlying conditions. The median length of the hospital stay was 6 days, and it was longer in children with underlying conditions (<0.001). The median cost of hospitalization per patient was $338 and was significantly higher in children with underlying conditions (p < 0.001). The estimated direct annual cost (not including the loss of parental work time and school absence) of varicella-related hospitalization in children under the age of 15 years in Turkey was $856,190 to $1,407,006. According to our estimates, 882 to 1,450 children are hospitalized for varicella each year, reflecting a population-wide occurrence of 466–768 varicella cases per 100,000 children. In conclusion, this study confirms that varicella-related hospitalizations are not uncommon in children, and two thirds of these children are otherwise healthy. The annual cost of hospitalization for varicella reflects only a small part of the overall cost of this disease, as only a very few cases require hospital admission. The incidence of this disease was higher in children <1 year of age, and there are no prevention strategies for these children other than population-wide vaccination. Universal vaccination is therefore the only realistic option for the prevention of severe complications and deaths. The surveillance of varicella-associated complications is essential for monitoring of the impact of varicella immunization.

1 July 2015 in Vaccine
Verified
Journal Article
Closed access
Ener Cagri DinleyiciEner Cagri Dinleyici
Ener Cagri Dinleyici
ZKZafer Kurugol
Zafer Kurugol
AKAtes Kara
Ates Kara
HTHasan Tezer
Hasan Tezer
MTMehmet Ali Tas
Mehmet Ali Tas
EAEmre Alhan
Emre Alhan

9 September 2023 in Journal of Pediatric Infection
Verified
Journal Article
Closed access
ABAnıl Doğan Bektaş
Anıl Doğan Bektaş
EYEmine Olcay Yasa
Emine Olcay Yasa
ZHZafer Habip
Zafer Habip
EKEsra Koçoğlu
Esra Koçoğlu